Sanofi Sarclisa combo gets Japanese nod for newly diagnosed multiple myeloma Ruchika Sharma27 Feb 2025 11:30 AM ISTParis: Sanofi has announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with...
Sanofi Sarclisa approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant Ruchika Sharma2 Feb 2025 10:45 AM ISTParis: Sanofi has announced that the National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a...
Sanofi Sarclisa approved in EU for newly diagnosed multiple myeloma Ruchika Sharma26 Jan 2025 1:30 PM ISTParis: Following the adoption of a positive opinion by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use...
Sanofi Sarclisa gains Chinese nod for treatment of adult patients with relapsed or refractory multiple myeloma Ruchika Sharma14 Jan 2025 1:30 PM ISTParis: Sanofi has announced that the National Medical Products Administration (NMPA) in China has approved Sarclisa, an anti-CD38 medicine,...
Sarclisa recommended for EU approval by CHMP to treat transplant-ineligible newly diagnosed multiple myeloma: Sanofi Ruchika Sharma17 Nov 2024 4:00 PM ISTParis: Sanofi has announced that the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) has adopted a...
USFDA nod to Sanofi Sarclisa in combo with bortezomib, lenalidomide, dexamethasone for newly diagnosed multiple myeloma not eligible for transpant Ruchika Sharma21 Sept 2024 2:25 PM ISTParis: Sanofi has announced that the US Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with bortezomib,...
Sanofi Sarclisa accepted for USFDA priority review for transplant-ineligible newly diagnosed multiple myeloma Ruchika Sharma27 May 2024 11:30 AM ISTParis: Sanofi has announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License...
Sanofi multiple myeloma drug Sarclisa phase 3 trial meets primary endpoint of progression-free survival Ruchika Sharma10 Dec 2023 11:30 AM ISTParis: Sanofi has announced that the Phase 3 IMROZ trial evaluating the investigational use of Sarclisa (isatuximab) in combination with...
Sanofi announces €300 million collaboration with Blackstone Life Sciences MD Bureau17 March 2022 10:43 AM ISTFor the Sarclisa subcutaneous formulation delivery, Sanofi has partnered with drug delivery technology innovator company Enable Injections, Inc. to...
Sanofi gets USFDA nod for Sarclisa, Carfilzomib, Dexamethasone combo to treat multiple myeloma Ruchika Sharma3 April 2021 11:00 AM ISTParis: Sanofi has announced that the U.S. Food and Drug Administration (USFDA) has approved Sarclisa (isatuximab) in combination with carfilzomib and...
Sanofi Multiple Myeloma Drug Sarclisa Gets European Nod Ruchika Sharma5 Jun 2020 9:30 AM ISTSarclisa is a monoclonal antibody (mAb) that binds to a specific epitope on the CD38 receptor of MM cells
FDA approves new therapy for progressive multiple myeloma Dr. Kamal Kant Kohli3 March 2020 9:34 AM ISTU.S. Food and Drug Administration hss approved Sarclisa (isatuximab-irfc), in combination with pomalidomide and dexamethasone, for the treatment of...
